Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 3/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonidine SCHEMBL5982 | 0.87 | MAPT (0.36) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| Clonidine SCHEMBL1369983 | 0.87 | MAPT (0.36) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| SCHEMBL10831788 | 0.87 | POLB (0.39) | HSP90AA1MAPTMEN1KMT2AATM | |
| Clonidine SCHEMBL10972183 | 0.85 | ADRA2A (0.36) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| Clonidine SCHEMBL3974275 | 0.85 | ADRA2A (0.36) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| Clonidine SCHEMBL1172959 | 0.85 | ADRA2A (0.36) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| Clonidine SCHEMBL9838987 | 0.85 | MAPT (0.35) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| Clonidine SCHEMBL40751 | 0.85 | ADRA2A (0.36) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| Clonidine SCHEMBL22127030 | 0.85 | MAPT (0.35) | HSP90AA1MAPTMEN1KMT2AHTR1D | |
| Clonidine SCHEMBL22127029 | 0.83 | MAPT (0.34) | HSP90AA1MAPTMEN1KMT2AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4287201-A | CONTAINING A 2-(SUBSTITUTED PHENYLIMINO)IMIDAZOLIDINE COMPOUND | MERCK & CO., INC. (US) | 1981-09-01 | — | — | US | claimed |
| EP-0821585-B1 | USE OF ALPHA 1L-AGONISTS IN THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-01-10 | — | — | EP | disclosed |
| US-7019021-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-03-28 | — | — | US | disclosed |
| US-6858594-B2 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG. (DE) | 2005-02-22 | — | — | US | disclosed |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-10-07 | — | — | US | disclosed |
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-06-19 | — | — | US | disclosed |
| EP-1285653-A1 | Use of alpha-1L agonists in the treatment of incontinence | Boehringer Ingelheim Pharma KG (DE) | 2003-02-26 | — | — | EP | disclosed |
| US-6268389-B1 | Treatment of urinary incontinence by administration of α1L-adrenoceptor agonists | BOEHRINGER INGELHEIM KG (DE) | 2001-07-31 | — | — | US | disclosed |
| EP-0821585-A1 | USE OF $g(a) 1L? AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1998-02-04 | — | — | EP | disclosed |
| WO-1996032939-A1 | USE OF α1L AGONISTS IN THE TREATMENT OF INCONTINENCE | BOEHRINGER INGELHEIM KG (DE) | 1996-10-24 | — | — | WO | disclosed |
| EP-0202461-A1 | Substituted derivatives of 2-(N-alkenyl-N-phenyl-amino) imidazoline, their acid addition salts, medicaments containing them and process for their preparation | BOEHRINGER INGELHEIM KG (DE) | 1986-11-26 | — | — | EP | disclosed |
| US-4581460-A | ANALGESICS | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1986-04-08 | — | — | US | disclosed |
| EP-0083729-B1 | SUBSTITUTED 1-BENZOYL-2-PHENYLIMINO-IMIDAZOLIDINES, THEIR ACID ADDITION SALTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1986-02-26 | — | — | EP | disclosed |
| EP-0083729-A1 | Substituted 1-benzoyl-2-phenylimino-imidazolidines, their acid addition salts, process for their preparation and pharmaceutical compositions containing them | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1983-07-20 | — | — | EP | disclosed |
| EP-0035393-A1 | Poultry feeds containing and methods of using anovulatory compounds, and novel anovulatory imidazolines | MERCK & CO. INC. (US) | 1981-09-09 | — | — | EP | disclosed |
| US-4287201-A | CONTAINING A 2-(SUBSTITUTED PHENYLIMINO)IMIDAZOLIDINE COMPOUND | MERCK & CO., INC. (US) | 1981-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114425-A1 | Compounds and methods for treating urinary incontinence | PDE3A, PDE3B, PDE2A | HSP90AA1 3235/4885MAPT 2876/4885MEN1 3795/4885 |
| US-20040198796-A1 | Compounds and methods for treating urinary incontinence | REN, ARG1, RXFP1 | HSP90AA1 2992/4885MAPT 2124/4885MEN1 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.